Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Cisplatin
Drug ID BADD_D00474
Description Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.
Indications and Usage For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.
Marketing Status approved
ATC Code L01XA01
DrugBank ID DB00515
KEGG ID D00275
MeSH ID D002945
PubChem ID 5702198
TTD Drug ID D0U5HU
NDC Product Code 16729-288; 25021-253; 0143-9505; 68554-0077; 0143-9504; 68001-283; 44567-509; 50711-0001; 44567-510; 63323-103; 0703-5747; 0703-5748; 44567-530; 60505-6277; 68083-163; 44567-511; 49452-2078; 54875-0001; 67184-0010; 68083-162; 70860-206; 49812-0009; 72659-864
UNII Q20Q21Q62J
Synonyms Cisplatin | cis-Diamminedichloroplatinum(II) | Platinum Diamminodichloride | Diamminodichloride, Platinum | cis-Platinum | cis Platinum | Dichlorodiammineplatinum | cis-Diamminedichloroplatinum | cis Diamminedichloroplatinum | cis-Dichlorodiammineplatinum(II) | NSC-119875 | Platino | Platinol | Biocisplatinum | Platidiam
Chemical Information
Molecular Formula PtCl2(NH3)2
CAS Registry Number 15663-27-1
SMILES N.N.Cl[Pt]Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hypoxia22.02.02.0030.000895%
Ileus07.13.01.0010.000448%
Ileus paralytic07.02.05.0010.000224%Not Available
Incontinence17.05.01.006; 07.01.06.011; 20.02.02.0040.000224%Not Available
Infection11.01.08.002--Not Available
Influenza like illness08.01.03.010--
Initial insomnia19.02.01.005; 17.15.03.0050.000112%Not Available
Injection site irritation12.07.03.027; 08.02.03.0270.000381%Not Available
Intermittent claudication24.04.03.0010.000112%Not Available
Interstitial lung disease10.02.01.033; 22.01.02.0030.001231%Not Available
Intestinal infarction24.04.08.008; 07.15.02.0060.000112%Not Available
Intestinal ischaemia24.04.08.001; 07.15.02.0010.000336%Not Available
Intestinal obstruction07.13.01.0020.000448%Not Available
Intestinal perforation07.04.06.0020.000224%Not Available
Intestinal ulcer07.04.06.0030.000168%Not Available
Intracranial pressure increased17.07.02.0020.000112%Not Available
Jaundice cholestatic09.01.01.0050.000280%Not Available
Lacrimation increased06.08.02.0040.000168%
Large intestine perforation12.02.03.005; 07.04.06.0050.000112%
Laryngeal cancer22.08.02.001; 16.19.03.0010.000168%Not Available
Laryngeal oedema23.04.01.005; 22.04.02.001; 10.01.05.0030.000112%
Lethargy19.04.04.004; 17.02.04.003; 08.01.01.0080.000672%
Leukocytosis01.02.01.0020.000728%
Leukoencephalopathy17.13.02.003--
Leukopenia01.02.02.0010.004891%Not Available
Liver disorder09.01.08.0010.000392%Not Available
Loss of consciousness17.02.04.0040.001063%Not Available
Lung consolidation22.01.02.0100.000280%Not Available
Lung disorder22.02.07.0010.000336%Not Available
Lung infiltration22.01.02.0040.000224%Not Available
The 7th Page    First    Pre   7 8 9 10 11    Next   Last    Total 20 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene